WASHINGTON, June 14, 2017 -- Winning Strategies Washington is pleased to announce that Bobby Clark, a recognized leader in health policy, has joined the firm as Of Counsel.
Bobby most recently served as a Counselor to former Secretary of Health and Human Services Sylvia M. Burwell. In this capacity, he advised Secretary Burwell on policy matters related to public health and science. Bobby worked closely with the Department’s key public health and scientific agencies, including the Food and Drug Administration and the National Institutes of Health and as a policy leader for the Department’s efforts on President Obama’s Precision Medicine Initiative and the Cancer Moonshot Initiative.
Bobby previously served as a health policy advisor in the U.S. House of Representatives from 2003-2010 as a senior staff member of the House Energy and Commerce Committee, Subcommittee on Health and for Representative Frank Pallone, Jr. of New Jersey. Mr. Pallone is currently the Ranking Member of the full Energy and Commerce Committee. During Bobby’s time on Capitol Hill, he contributed to a number of legislative achievements, most notably the Affordable Care Act.
In serving as Of Counsel to the firm, Bobby will be focused on adding new health care clients and expanding service offerings, including detailed policy analysis of health care issues.
“Especially now, when clients have to navigate an immensely complicated health care policy and political landscape, Bobby is an incredible addition to our team. Bobby is also a longstanding friend and colleague, and we are thrilled to bring him back to his Jersey roots,” said Donna Mullins, Managing Partner of the firm.
“This is sort of a homecoming for me. New Jersey is home to so many organizations that are leading the way and innovating in health care. I can’t wait to roll up my sleeves and get to work helping guide clients’ legislative, regulatory and policy objectives,” added Bobby.
Prior to joining HHS, Bobby worked at PwC's Health Research Institute, where he led the Institute’s analysis of regulatory and policy initiatives impacting the pharmaceutical and life sciences industries. While at PwC, Bobby also advised leading healthcare companies on shifting trends in the US health care marketplace.
Contact: Chelsey Penrod Hickman 202-589-0800


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



